Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Must have received: curative intent therapy

Completion of any curative intent therapies resulting in no evidence of disease (e.g., R0 resection) for stage I - IV CRC and has completed all planned adjuvant/standard therapies per the discretion of the evaluating clinician.

Cannot have received: systemic anti-cancer agents

Exception: protocol-specified anti-cancer therapy

Concurrent treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any type.

Cannot have received: oral tyrosine kinase inhibitor (pexidartinib, imatinib, nilotinib)

Use of pexidartinib, any other oral tyrosine kinase inhibitor (e.g., imatinib or nilotinib), or any biologic treatment targeting CSF1 or CSF1R within the past 4 weeks.

Cannot have received: biologic treatment targeting CSF1 or CSF1R

any biologic treatment targeting CSF1 or CSF1R within the past 4 weeks.